Monthly Archives

February 2019

Antihistamínicos H1

Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Nonsedative Properties.

By | Articles about Bilastine
Kawauchi H, Yanai K, Wang DY, Itahashi K, Okubo K.

Antihistamines targeting the histamine H₁ receptor play an important role in improving and maintaining the quality of life of patients with allergic rhinitis. For more effective and safer use of second-generation drugs, which are recommended by various guidelines, a classification based on their detailed characteristics is necessary. Antihistamines for first-line therapy should not have central depressant/sedative activities.
Among the non-sedating group, fexofenadine and bilastine are classified into “non-brain-penetrating antihistamines”.
This review summarizes that the non-brain-penetrating antihistamines should be chosen for the first-line therapy of mild allergic rhinitis.

This document is only available for registered healthcare professionals

Login

The long duration of action of the second generation antihistamine bilastine coincides with its long residence time at the histamine H1 receptor

By | Articles about Bilastine
Bosma R, van den Bor J, Vischer HF, Labeaga L, Leurs R

Bilastine shows a long drug-target residence time at the H1 receptor (73 ± 5 min) and this results in a prolonged H1 receptor antagonism in vitro (Ca2+ mobilization in Fluo-4 loaded HeLa cells), following a washout of unbound antagonist. Hence, the long residence time of bilastine can explain the observed long duration of drug action in vivo.

This document is only available for registered healthcare professionals

Login
Antihistamínico novel

Bilastine – A Novel Antihistamine for Allergic Rhinitis and Chronic Spontaneous Urticaria

By | Articles about Bilastine
Kraft JN, Sussman GL

Bilastine has a proven, long-term safety record with use by over 71 million patients in over 104 countries. This novel, second generation antihistamine is non-sedating due to the fact that it does not cross the blood brain barrier. As well, bilastine is not metabolized and does not interact with CYP450.

This document is only available for registered healthcare professionals

Login
F1 simulador

Bilastine safety in drivers who need antihistamines: new evidence from high-speed simulator driving test on allergic patients

By | Articles about Bilastine
Demonte A, Guanti MB, Liberati S, Biffi A, Fernando F, Fainello M, Pepe P

This study is the first done in patients with allergic rhinitis and/or chronic urticaria using a F1-high speed simulator-driving test evaluating subjects’ performance under bilastine treatment.

This document is only available for registered healthcare professionals

Login
Estudio de bilastina en pacientes japoneses

One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases

By | Articles about Bilastine
Yagami A, Furue M, Togawa M, Saito A, Hide M.

A number of second-generation non-sedating antihistamines are used in clinical practices over the world. However, long-term safety and efficacy have not been proved high level evidence based medicine. 
In conclusion, long-term treatment with bilastine 20 mg once daily for 52 weeks is safe and well tolerated in Japanese patients with hronic spontaneous urticaria (CSU) or pruritus associated with skin diseases. Bilastine improved disease symptoms of both conditions early in treatment, and the efficacy was maintained throughout the treatment.

This document is only available for registered healthcare professionals

Login
Alergológica 2015

Alergológica 2015: A National Survey on Allergic Diseases in the Spanish Pediatric Population

By | Selected articles
Ojeda P, Ibáñez MD, Olaguibel JM, Sastre J, Chivato T; investigators participating in the National Survey of the Spanish Society of Allergology and Clinical Immunology Alergológica 2015.

The findings of Alergológica 2015 show a notable increased frequency of allergic rhinitis, drug allergy, and food allergy. The frequency of other allergic conditions remained unchanged, except for asthma, whose frequency decreased, as in adult patients.

This document is only available for registered healthcare professionals

Login
bilastina en pacientes japoneses

Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects

By | Articles about Bilastine
Togawa M, Yamaya H, Rodríguez M, Nagashima H.

Bilastine exhibits similar single- and multiple-dose pharmacokinetic and pharmacodynamic characteristics in healthy Japanese subjects compared with those observed in Caucasian subjects in previous studies.

This document is only available for registered healthcare professionals

Login
Biomarcadores urticaria

Cutting Edge: Biomarkers for Chronic Spontaneous Urticaria

By | Selected articles
Folci M, Heffler E, Canonica GW, Furlan R, Brunetta E.

Chronic spontaneous urticaria (CSU) is defined by the appearance of wheals and a variable presence of angioedema which persists for at least 6 weeks. Some groups are trying to detect molecules which would be able to help clinicians in reaching a proper diagnosis.

This document is only available for registered healthcare professionals

Login

The relationship between IL-17A and IL-22 expression and clinical severity in patients with moderate/severe persistent allergic rhinitis

By | Selected articles
Shahsavan S, Pirayesh A, Samani OZ, Shirzad H, Zamani MA, Amani S, Kazemi SM, Moghni M, Deris F, Bageri N, Salimzadeh L, Tavakoli G, Arjenaki MG.

The aim of the present study was to investigate the levels of IL-22 and IL-17A in AR patients and their association with clinical severity of persistent allergic rhinitis (PAR).

This document is only available for registered healthcare professionals

Login

La información que está a punto de visualizar está dirigida únicamente a los profesionales sanitarios aptos para prescribir o dispensar medicamentos. La correcta utilización de su contenido requiere de formación como profesional sanitario.

Debe hacer clic en Aceptar para confirmar que es usted profesional de la salud y continuar con la navegación.

ACEPTAR